Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study

Anti-angiogenic and mammalian target of rapamycin inhibitors have shown efficacy in solid tumours. Reported combination of both drugs was deemed to be too toxic. Due to a potential favourable safety profile of axitinib (AX), a phase I study combining everolimus (EV) and AX for solid tumours was explored.

Patients (pts) with advanced cancers were enrolled in an escalation phase I study to investigate the safety of the combination. Pharmacokinetic profile and functional vascular imaging were performed. An extension to pts with naive metastatic renal cell carcinoma (MRCC) was explored.

15 pts were included over three different dose levels (DLs); DL 0: AX 3 mg BID (twice daily)/EV 5 mg OD (once daily); DL 1: AX 5 mg BID/EV 5 mg OD and DL 2: AX 5 mg BID/EV 10 mg OD for 28 d. One dose-limiting toxicity (DLT) was reported at DL 0: grade (Gr) III diarrhoea and one DLT at DL 2: Gr III asthenia. Three severe adverse events (AEs) in two pts were unexpected: jaw osteonecrosis, recurrent renal failure and cardiomyopathy. Maximum tolerated dose (MTD) was level 2. After 1st cycle, Gr III or Gr II AEs of interest were mainly asthenia, diarrhoea and anorexia. All pts but one showed tumour shrinkage. Partial responses (PRs) were seen in one pt with bladder carcinoma and in one pt in 1st line MRCC in the escalating phase. In the extension phase in naive MRCC treated at MTD, five pts had a PR and one pt had a prolonged stable disease.

The recommended dose for phase II is AX 5 mg BID/EV 10 mg OD.

European journal of cancer (Oxford, England : 1990). 2017 Sep 05 [Epub ahead of print]

Alain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, Laurence Digue, Christine Chevreau, Anne Gimbert, Emmanuelle Chauzit, Rémi Sitta, François Cornelis, Julien Asselineau, Richard Aziza, Amaury Daste, Cathy Quemener, Jessica Baud, Andréas Bikfalvi, Delphine Pedenon-Périchout, Adelaïde Doussau, Mathieu Molimard, Jean-Pierre Delord

Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Clinical Investigational Center, CIC, INSERM CIC 1401, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France. Electronic address: ., Department of Medical Oncology, Cancer University Institute of Toulouse Oncopole, Toulouse, France., Methodology Research Unit, Bordeaux University Hospital, Bordeaux, France., Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Clinical Investigational Center, CIC, INSERM CIC 1401, Bordeaux University Hospital, Bordeaux, France., Pharmacovigilance Unit, Bordeaux University Hospital, Bordeaux, France., Clinical Pharmacology Unit, Bordeaux University Hospital, Bordeaux, France., Department of Radiology, Bordeaux University Hospital, Bordeaux, France., Department of Radiology, Cancer University Institute of Toulouse Oncopole, Toulouse, France., Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France., INSERM U1029, Bordeaux, France.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe